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INTRODUCTION
Tobacco smoking entails a two-faced risk for human 
health: the risk of organic disease due to the exposure 
to toxic and carcinogenic chemicals, produced by to-
bacco burning, and the risk of neuro-behavioral effects 
(addictive risk), due to the exposure to nicotine that is 
a strong psychoactive compound able to induce depen-
dence. In particular, tobacco when burning produces 
more than 7000 chemicals, of which hundreds are toxic 
and about 70 are carcinogens [1]. Nicotine is a tertiary 
amine composed of a pyridine and a pyrrolidine ring, 
and is the primary alkaloid found in Solanacee and in 
particular in the plant Nicotiana tabacum. The leaves 
have a high nicotine content (accounting for 96-98% of 
the total alkaloid content) [2] and undergo a complex 
production process, needed to obtain products ready for 
human consumption by smoking, chewing, and snuffing. 
In tobacco, nicotine is largely present as the levorotary 
(S)- or (-)-isomer (99.4 - 99.7% of whole nicotine con-
tent) which is the most physiologically active isomer [3].
Nicotine belongs to the group of the cholinergic ago-
nists and binds the acetylcholine receptors at ganglia, at 
neuromuscular junctions and in the brain [4]. Nicotine 
from the tobacco smoke is rapidly adsorbed into the 
bloodstream and metabolized in the liver. Due to its 
lipophilic character, nicotine penetrates easily through 
the blood-brain-barrier reaching the brain in just sec-
onds (10-20 s) [3] after inhalation, and therefore pro-
ducing central effects. Nicotine is able to influence cog-
nitive functions, emotions and the reward processing, 
all of which play a key role in addiction [5-7]. Acute 
toxicity of nicotine, expressed as median lethal dose 
(LD50), is 0.5-1.0 mg/kg of body weight for humans 
[8]. Intoxication may occur from dermal absorption or 
accidental ingestion, especially by children for which 
the LD50 is only 0.1 mg/kg [9]. Accidental nicotine 
poisoning may occur by cigarette but also by nicotine 
gum or by refill liquids for electronic cigarettes [10-11] 
As regards the teratogenic risk of nicotine exposure, 
the Food and Drug Administration (FDA) classifies 
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Abstract
This study investigates the transfer of nicotine from lactating dams to their offspring 
through breast milk, in the frame of a research focused to ascertain toxicological and 
neuro-behavioural effects on pups as consequence of either unavoidable (“yoked & 
forced”) or voluntary (“freely-chosen”) maternal nicotine exposure. To this aim, plas-
matic concentrations of nicotine and cotinine were determined by LC-MS/MS in Wistar 
rat pups whose mothers were orally administered with nicotine during lactation. Mothers 
were divided into a voluntary drinking group, an unavoidable consumption group, and 
controls. The limits of detection and quantification of the LC-MS/MS method were 0.20 
and 0.65 ng/mL, respectively. Within-laboratory reproducibility (CV%) was <12%, with 
recovery of 86.2-118.8%. Results showed the presence of nicotine in 67% of samples 
from freely-chosen consumption group (1.30 ± 0.31 ng/mL) and in 60% of samples from 
yoked-consumption group (1.19 ± 0.62 ng/mL); cotinine was found in all the samples 
from freely-chosen (1.92 ± 0.77 ng/mL) and yoked-consumption groups (1.43 ± 0.30 ng/
mL). Data provide an evidence-based support to maternal/offspring nicotine transfer as 
function of different ways of oral exposure.
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nicotine as “reproductive or developmental toxicant” 
[12]. Nicotine crosses the placenta and hence even 
small amounts could be toxic during pregnancy. Where-
as the dangerous effects of smoking during pregnancy 
have been extensively depicted, it is not clear yet if and 
how nicotine affects neonatal development when expo-
sure occurs during lactation. During pregnancy, mater-
nal smoking is related to cognitive deficits in the off-
spring and to behavioural abnormalities as hyperactivity 
and attention deficit disorders [13]. 
In our perspective, it is often neglected that, further 
to smoke breathing by the baby, nicotine is secreted 
into the breast milk [14]. As stated before, nicotine is a 
lipophilic compound, so the likelihood of passing from 
the mother to the offspring through breast milk could 
be high. Therefore, major concerns should arise when 
mothers, which might have stopped smoking when re-
alizing to be pregnant, do start smoking again during 
the crucial period of lactation, as well for mothers who 
continue and never quit smoking. On the other hand, 
it is also useful to obtain information about the risks 
and possible consequences of a kind of uncontrollable, 
unavoidable intake, often used in pharmacological lit-
erature: to this purpose, we included a group with a 
fully yoked nicotine exposure. In our study, lactating 
offspring were investigated after postnatal nicotine ex-
posure offered to their rat dams. With the aim to assess 
nicotine transfer through milking, maternal exposure 
was obtained in two ways: (1) freely controllable drink-
ing by own choice, with a relatively higher dosage of 
nicotine in water, and (2) forced and unavoidable in-
take, with a lower and yoked dosage of nicotine in tap 
water.
To these aims, it is required to provide a reliable 
quantification of nicotine actually detectable in the 
biological samples; as a biomarker, nicotine is highly 
specific even if not suitable for a routine clinical use, 
because of nicotine’s short half-life [3]. Nevertheless, 
in most mammalians about 70 – 80% of nicotine is ex-
tensively metabolized to the 5’-hydroxy-nicotine (coti-
nine), while other metabolites are also produced [3]. 
Cotinine is present in the blood in much higher concen-
trations than those of nicotine and it has a much longer 
plasmatic half-life, since the mean half-life is 16 h for 
cotinine with respect to just 2 h for nicotine [3]. For 
these reasons, cotinine is considered a highly specific 
and sensitive biochemical marker of nicotine exposure 
and it is widely used in clinical practice and for animal 
experimentation studies. However, cotinine in the pups’ 
body is, in itself, a marker of maternal exposure, but 
not necessarily a proof of nicotine transfer nor a marker 
for actual offspring exposure. Indeed, detection only 
of this metabolite in the pups’ body cannot dismiss the 
possibility that cotinine alone is transferred through the 
milk, and that nicotine never entered the pups’ body. 
To date, many analytical methods have been pub-
lished to measure nicotine and cotinine in different 
biological samples such as serum/plasma, urine, saliva, 
hair, meconium. The most used analytical methods are 
Radio Immuno Assay (RIA) [15], Enzyme Immuno 
Assay (EIA) [16-18], Gas-Chromatography (GC) [17, 
19, 20], and Liquid-Chromatography (LC) [17, 21-
27]. In particular, among LC techniques, the liquid 
chromatography-tandem mass spectrometry (LC-MS/
MS) provides a rapid, sensitive and selective tool for the 
determination of nicotine and all its metabolites [21-
27]. The main focus of the present study was to inves-
tigate the actual passage of nicotine from dams to their 
offspring through breast milk. This is a crucial step, in 
order to correctly evaluate the neurobehavioral con-
sequences of “direct” nicotine exposure, if confirmed, 
rather than “mere” exposure to maternal cotinine, if not 
so, within vulnerable, developing brains. In particular, 
we have been able to detect levels of nicotine, and not 
only of its major metabolite, cotinine.
Nicotine and cotinine were determined in the off-
spring plasma, which was collected with extreme care: 
the time of sacrifice was planned in a window between 
40 and 50 min after a breastfeeding bout lasting at least 
18 min consecutively. Pups’ samples were indeed taken 
45 min following the end of a lactation episode. A high 
sensitive and specific LC-MS/MS procedure was specif-
ically set up for identification and quantification of nico-
tine and cotinine in the reduced volumes of plasma that 
can be obtained from these small animals. The analyti-
cal procedure and its validation are described in detail 
in the present paper. Within the experimental groups 
submitted to this kind of nicotine exposure, only some 
of the animals were sacrificed for determining plasmatic 
nicotine/cotinine. The other siblings underwent behav-
ioural tests to investigate the impact of nicotine expo-
sure on social and emotional behaviour of the adoles-
cent offspring: this part of the study was described in a 
recent paper by some of the present authors [28]. 
MATERIALS AND METHODS
Ethical note
All experimental procedures were formally approved 
by the Italian Ministry of Health (formally valid during 
years 2014-2016, licence to GL), and were conducted 
in close agreement with the European Communi-
ties Council Directive (2010/63/EU) and Italian Law 
(D.Lgs 26/14).
All efforts were made to minimize animal suffering, 
to reduce the number of animals used, and to utilise 
alternatives to in-vivo techniques, if available.
Sample collection for method development  
and validation
Pooled blood samples from adult male Wistar rats 
spiked with standards solutions were used to perform 
preliminary method development and validation. Blood 
was collected from the trunk into vials with heparin to 
prevent clotting, then centrifuged at 2500 r/min for 20 
min at 4 °C. Plasma was transferred into tubes and then 
stored at -80 °C until further processing.
Subjects and housing
Twenty-four female and twelve male Wistar rats, orig-
inally purchased from Charles River (France) were bred 
in our laboratory. Two females were housed with one 
male in polycarbonate cages (48.0 x 26.5 cm, height 
21.0 cm), with sawdust bedding and a metal top. Af-
ter 4 days of mating, male rats were removed. Sixteen 
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females were actually pregnant and were housed indi-
vidually starting from the 16th day of gestation. Dams 
were daily checked for delivery; births occurred within 5 
days. On the day after birth, designated as PND 1, cull-
ing was performed to keep 5 male and 3 female pups 
per mother.
Dams and their litters were maintained under stan-
dard facility rearing conditions (cage cleaning once a 
week) in an air-conditioned room (temperature 21 ± 1 
°C, relative humidity 60 ± 10%) on a reversed 12 : 12 
hours light : dark cycle (lights on from 18:45 to 6:45), 
with water and rodent food pellets (Altromin - Rieper 
Maintenance Diet for Rats and Mice purchased from 
A. Rieper S.p.A., VanDOIes, Bolzano, Italy) being 
available ad libitum.
Neonatal treatments and procedures
Dams were divided in two batches used to compose 
three experimental groups, according to the day of de-
livery (pups belonging to each batch were born within a 
range of 3 days): the first 6 dams to give birth (batch A) 
were given a choice between two identical bottles, con-
taining either a 3.5 mg/L nicotine solution or tap wa-
ter (freely choosing drinking group); other 5 dams who 
gave birth afterwards (batch B) were provided with two 
identical bottles, both with an equal nicotine solution 
(forced and yoked intake group). The concentration of 
nicotine for batch B has been calculated based on the 
actual intake of batch A. Thus, as calculated daily, each 
of the two bottles for batch B contained a concentra-
tion that was corresponding to half of daily nicotine 
intake, measured by the free-choice fluid consumption 
already shown by dams on batch A. The third group 
was composed of 5 dams who received two identical 
bottles, both with tap water (controls). To avoid a bias 
represented by potential preferences for either the right 
or the left side of the cage, the position of the nicotine 
bottle was daily reversed as previously reported [29-
30]. Apart from the different solutions in the drinking 
bottles, environmental condition were the same among 
groups.
Treatments with nicotine and water bottles started at 
PND 3 ± 1 and lasted until PND 12 ± 1. Lactating dams 
belonging to all groups drank comparable amounts of 
fluid (66.35 ± 1.20 mL); daily nicotine intake fluctuated 
over the 10 treatment days, ranging between 0.20 - 0.62 
mg/kg ingested with 29.74 ± 2.56 mL of fluid (average 
preference 45.9%), and 0.12 - 0.34 mg/kg ingested with 
all drunk fluid, for the “free-choice” drinking and the 
“forced/yoked” intake groups, respectively. “Actively 
choosing” mothers drunk nicotine at their wish, where-
as for “forced/yoked” dams were unavoidably obliged to 
drink the nicotine solution whenever they were thirsty. 
After PND 12 ± 1, all dams were returned to tap water.
Two male and one female pups per dam were de-
capitated for collecting blood from the trunk at PND 
12 ± 1 at specific timing (range: 40 to 50 min after a 
breastfeeding bout lasting at least 18 min consecu-
tively). Blood samples were collected to obtain plasma, 
as described in previous 2.2 section, for subsequent 
quantitative determination of nicotine and cotinine. 
Remaining pups were submitted to behavioural tests 
during adolescence, according to procedures published 
elsewhere [28].  
Chemicals and reagents
Nicotine hydrogen tartrate salt used for nicotine ad-
ministration was purchased by Sigma-Aldrich (St. Lou-
is, MO). Heparin solution for sample collection was 
obtained by 5000 U.I./mL Heparin Vister provided by 
Marvecs Pharma Services S.r.l. (Milan, Italy). Metha-
nol, diethyl ether, ethyl acetate and acetonitrile used 
for sample preparation and LC-MS/MS analysis were 
HPLC or analytical grade and were purchased from 
Sigma-Aldrich. Water was purified by Synergy-UV-Sys-
tem (Millipore, Bedford, MA, USA). Ammonium bi-
carbonate, (-)-nicotine and (-)-cotinine were provided 
by Sigma-Aldrich. OASIS HLB SPE cartridges (3 mL, 
60 mg) were supplied by Waters (Milford, MA, USA). 
(±)-nicotine-d4 (100 µg/mL, 1 mL, 98 % D) was used 
as Internal Standard (IS) and was provided by Sigma-
Aldrich (St. Louis, MO). 
The nicotine solution for the free-choice consump-
tion group (batch A) was freshly prepared by dissolving 
10.0 mg of nicotine hydrogen tartrate salt in 1000 mL 
of tap water, to obtain a final nicotine concentration 
of 3.5 mg/L. The nicotine solution for the forced con-
sumption group (batch B) was freshly prepared each 
day, by dissolving an appropriate amount of nicotine; 
this, was calculated on the basis of daily chosen nicotine 
intake of the free-choice consumption group, already 
shown for the corresponding post-natal day of exposure 
in batch A, and then halved (ranging from 0.26 mg to 
1.44 mg, on average 1.15 mg). The 5% ammonia solu-
tion was prepared by diluting an 20% ammonia solution 
(Carlo Erba Reagents, Milan, Italy). The 20 mM am-
monium bicarbonate solution was obtained by dissolv-
ing 1.58 g of ammonium bicarbonate in 1000 mL of 
purified water. 
Standards and matrix calibration curve for LC-MS/
MS analysis
A 1 mg/mL stock solution of each standard (nicotine 
and cotinine) was prepared in methanol, and from these 
solutions, 10 μg/mL dilutions were prepared. Stock so-
lutions, regularly analysed at fixed times to assess their 
stability in the time, did not exhibit degradation of the 
analytes up to six month
A mixture of standards was then prepared to obtain 
working solutions at dilutions of 100, 50 and 10 ng/mL. 
IS working solution was prepared by serial dilutions to 
obtain a concentration of 98 ng/mL. Working solution, 
stored at 4 °C, were prepared daily and used to spike 
blank (i.e. without nicotine and cotinine) plasma to ob-
tain the matrix-matched calibration. Calibration curve 
for determination of linearity and quantification was 
constructed by spiking 0.5-mL-aliquots of blank plasma 
with 25 µL of 98 ng/mL IS (final concentration: 4.9 ng/
mL) and with working solutions to obtain 5 concentra-
tion points: 0.65, 1.30, 2.55, 5.10 and 10.20 ng/mL for 
nicotine and 0.65, 1.31, 2.63, 5.25, and 10.50 ng/mL 
for cotinine. Three set of replicates of each calibration 
levels on three different days were used to determine 
linearity.
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Sample preparation
Each 0.5-mL-aliquot of offspring plasma was spiked 
with a methanolic solution containing known amount 
of IS (25 µL, 98 ng/mL) and then was added to 0.5 
mL of 5% ammonia solution. The mixture was vortex-
mixed and then loaded on the OASIS HLB SPE car-
tridge which was previously conditioned with 3 mL of 
methanol and 3 mL of purified water. After the washing 
step with 3 mL of purified water, the analytes were elut-
ed with 2 mL of ethyl acetate/diethyl ether 2: 1 (v/v). 
The extract was then evaporated under nitrogen stream 
and the dry residue dissolved in 100 μL of a mixture of 
methanol and 20 mM ammonium bicarbonate (9 : 1, 
v/v) for LC-MS/MS analysis.
LC-MS/MS analysis
Analyses were carried out using a LC system Per-
kin Elmer Series 200 Micro Pump equipped with a 
PE Series 200 auto sampler (Perkin Elmer, USA). The 
chromatographic separations were obtained under gra-
dient conditions at room temperature (25 °C) using a 
reverse phase HPLC column Gemini-NX C18 110A 
(150 x 4.60 mm, I.D. 5 μm) (Phenomenex, USA) with 
a Gemini-NX C18 guard column (4 mm x 3 mm I.D.) 
(Phenomenex, USA). The mobile phase was composed 
of ammonium bicarbonate 20 mM (mobile phase A) 
and acetonitrile (mobile phase B) and the flow rate was 
0.8 mL/min. The gradient profile began at 90% A and 
changed to 5% in 9 min, then returning to 90% A in 0.3 
min and held for 3 min. 
The API 3000 triple quadrupole mass spectrometer 
(AB Sciex, Canada) was equipped with an Electro 
Spray Ionization (ESI) source, and was set in positive 
ionization mode with a source temperature of 450 °C 
and an ionspray voltage of 5500 V; ultra-pure nitrogen 
was used as curtain and collision gas, and ultra-pure air 
was used as nebulizer and auxiliary gas. The full iden-
tification of the analytes was achieved according to the 
criteria of the Commission Decision 2002/657/EC con-
cerning the performance of analytical methods and the 
interpretation of results [31] and the peak areas of the 
analytes were computed using the software Analyst ver-
sion 1.4 from AB Sciex.
According to the Decision 2002/657/EC, the 4 points 
required for identification by LC-MS/MS technique 
(“identification points”) were yielded using the MRM 
(Multiple Reaction Monitoring) mode with one precur-
sor ion and two product ions (two transitions). Table 1 
reports the optimized parameters of nicotine, cotinine 
and IS and Figure 1 (a and b) shows Positive-ESI MS/
MS spectra and proposed fragmentation pathways for 
nicotine and cotinine) [18, 21, 22, 24-26]. Figure 2 
shows a representative extract ion chromatograms for 
nicotine, cotinine, and IS in a spiked plasma sample
Statistical analysis
Analytical data, expressed as mean ± standard devia-
tion, were analysed using repeated-measures analysis of 
variance (ANOVA) to compare plasmatic concentra-
tion of both nicotine and cotinine found in the free-
choice drinking group versus the yoked-intake unavoid-
able consumption one.
RESULTS
Validation of LC-MS/MS analytical procedure
The linearity was assessed by the matrix-matched cal-
ibration curve, built with five calibration levels for nico-
tine and cotinine in the selected concentration intervals 
described above. The linear regression analysis showed 
a correlation coefficient greater than 0.998. As regards 
the Limit Of Detection (LOD) and the Limit Of Quan-
tification (LOQ) (i.e. the lowest concentrations of the 
analyte that can be reliably detected and measured, re-
spectively), in terms of signal-to-noise ratios ≥ 3 and ≥ 
10, they resulted respectively equal to 0.20 ng/mL and 
0.65 ng/mL for both nicotine and cotinine. Analytical 
selectivity and specificity of methods were assessed di-
rectly onto the chromatograms obtained from the blank 
and from spiked plasma matrices. The occurrence of 
possible extra-peaks was tested by monitoring the two 
MRM transitions characteristic for each investigated 
compound onto the blank matrix chromatograms, in 
the retention time window expected for elution of the 
analyte. Repeatability expressed as intra-day coefficient 
of variation (CV%) was evaluated by analysing daily 
four replicates of samples at three concentration levels: 
0.65 (corresponding to LOQ value), 2.55 and 10.20 ng/
mL for nicotine; 0.65 (corresponding to LOQ value), 
2.63 and 10.50 ng/mL for cotinine. At the LOQ values, 
the intra-day CV% resulted below 11% for nicotine and 
below 10% for cotinine. At the two higher concentra-
tion levels intra-day CV% ranged between 2.39% and 
7.01% for nicotine, and between 2.09% and 6.37% for 
cotinine. To evaluate the within-laboratory reproduc-
ibility and recovery, the same series were analysed over 
three different days. The within-laboratory reproduc-
Table 1 
Precursor and most abundant product ions and their optimized parameters
Analyte Transition Collision 
Energy (eV)
Declustering 
Potential (V)
Retention 
time (min)
Nicotine 163 > 130a
163 > 117
30
35
40
40
5.7
Cotinine 177 > 80a
177 > 98
35
30
40
40
4.3
Nicotine-d4 (IS) 167 > 134a
167 > 121
30
35
40
40
5.7
a Most abundant product ion
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ibility expressed as inter-day reproducibility CV% was 
below 12.0% for both nicotine and cotinine at LOQ val-
ues and below 9.0% at other concentration levels within 
the matrix calibration interval (Table 2). Recovery per-
centage within calibration interval ranged from 86.2% 
to 118.8% for both the analytes.
Biochemical markers of nicotine exposure through 
maternal milk 
Biochemical quantification performed in the off-
spring plasma confirmed the presence of nicotine in 
67% of samples belonging to the free-choice drinking 
group (1.30 ± 0.31 ng/mL) and in 60% of samples be-
longing to the “yoked” intake group (1.19 ± 0.62 ng/
mL). Cotinine was conversely determined in all (100%) 
of samples belonging to the free-choice drinking group 
(1.92 ± 0.77 ng/mL) and in all (100%) of samples be-
longing to the “yoked” intake group (1.43 ± 0.33 ng/
mL). No traces of nicotine and cotinine were found in 
plasma of control rats, as expected. Analytical data were 
analysed using repeated-measures analysis of variance 
(ANOVA) to compare plasmatic concentration of both 
nicotine and cotinine found in the free-choice drink-
ing group versus the “yoked” intake one. No significant 
differences were found between the two experimental 
groups (F(1,5) = 0.09, P = 0.78, NS). These results 
were subsequently considered to evaluate the results of 
the behavioural tests in the adolescent subjects.
DISCUSSION
The main focus of the present study was to ascertain 
the nicotine transfer by maternal milk to lactating pups 
and, to this aim, a specific model of nicotine exposure 
and an appropriate LC-MS/MS procedure suitable for 
determining plasmatic nicotine and cotinine level of 
pups were set up. In particular, the study was focused 
on two maternal exposure scenarios, for investigat-
ing if the way by which dams assume nicotine orally 
could affect lactating offspring. The two experimental 
groups were composed from mothers exposed to either 
free-choice ( i.e., freely choosing between bottles) or 
unavoidable (“forced / yoked”) oral consumption of 
nicotine (through drinking water). Furthermore, the 
nicotine exposure through milk in suckling pups was 
studied as one of the most “natural ways” of exposure 
to nicotine that may occur in a human baby. 
Cotinine, that is usually detected alone in the off-
spring, may be produced in the liver of dams and then 
transferred through milk. So, its detected presence does 
not necessarily imply nicotine transfer from mother 
with then production by the liver of pups. Only a reli-
able detection of the actual presence of nicotine in the 
Figure 1
Positive-ESI MS/MS spectra and proposed fragmentation pathways for nicotine (a) and cotinine (b).
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offspring plasma could give an evidence-based prove 
of nicotine transfer by maternal milk. It is evident that 
such a crucial information is a base on which to rely 
for evaluating related effects and long-term sequelae. 
So, it was crucial to provide the evidence and proof of 
nicotine transfer by an analytical procedure suitable for 
quantifying plasma nicotine and cotinine in the present 
experimental conditions. For the preparative phase of 
our analysis,  different solid phase extraction cartridges 
with different eluting solvents were tested and OASIS 
HLB SPE cartridges yielded the best recovery for both 
the two analytes, among the various tested procedures.
Plasma samples (taken 45 min after a bout of lac-
tation, not with random timing as is usually the case) 
Figure 2
Representative extract ion chromatograms for nicotine, cotinine, and nicotine d4 (IS) in a spiked plasma sample.
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underwent a previous clean-up/concentration step by 
Solid-Phase Extraction (SPE) cartridges. Subsequently, 
the obtained extracts were reconstituted with an appro-
priate solvent and injected into the LC-MS/MS system. 
The LC-MS/MS technique coupled to SPE clean-up 
/ concentration of samples allowed the use of small 
amount of samples without loss of analytical sensitivity 
and specificity. Evaluated performance characteristics 
of the developed analytical procedure were: linearity, 
selectivity/specificity, limit of detection (LOD), limit of 
quantification (LOQ), repeatability (intra-day CV%), 
within-laboratory reproducibility (inter-day CV%), and 
recovery. Obtained results from nicotine exposed rats 
were then compared with those from non-exposed rats, 
belonging to the control group.
The criteria for molecular identification are those of 
liquid chromatography coupled to tandem mass spec-
trometry and it was performed by checking the match-
ing of the relative retention time observed for the ana-
lyte peaks in samples compared to methanolic standard 
analytes, with a tolerance of ± 2.5%. Moreover, the two 
transitions from the analyte molecular peak were moni-
tored with a signal-to-noise ratio greater than 3. All ion 
ratios of samples were within the recommended toler-
ances as required by Decision 2002/657/EC [31] when 
compared with standards. The within-laboratory repro-
ducibility (inter-day CV%) was below 12.0% for both 
nicotine and cotinine at LOQ values, and below 9.0% at 
other concentration levels within the matrix calibration 
interval. The recovery ranged from 86.2% to 118.8% 
for both the analytes. These calculated performance 
characteristics showed that the procedure is suitable 
for clinical studies and even for animal toxicology ex-
perimentations conducted on rodents or other similarly 
small animals, whose available plasma volumes are gen-
erally just few microliters. 
The analytical procedure herein presented was ap-
plied to investigate whether nicotine passes from dams 
to their offspring through breast milk and to quantify 
plasmatic nicotine and its major metabolite cotinine in 
plasma from Wistar rat pups whose mothers were orally 
administered with nicotine solutions during ten days of 
the lactation period. Analytical results confirmed that 
this passage exists and that nicotine and cotinine are 
detectable in the plasma of the offspring after a bout 
of lactation. 
Comparison between the two nicotine treated groups 
showed no reliable nor significant differences in nico-
tine and cotinine concentrations. As for this finding, 
some considerations may be put forward. It seems that, 
during transfer, some kind of rate-limiting ceiling was 
reached. Indeed, dams under a free-choice condition 
voluntarily ingested a remarkable quantity of nico-
tine, available from one of the bottles; a corresponding 
amount of nicotine, split into the two bottles, was pro-
posed to dams under a yoked intake and an evidently 
unescapable way of exposure. Due to these presenting 
ways, “freely choosing” mothers consumed nearly dou-
ble concentrated nicotine, from half volume of a bitter 
solution, than “yoked” dams; one could therefore ex-
pect nicotine and/or cotinine levels in the pups to differ 
accordingly, which was not the case.
The similar levels of nicotine in either group may be 
explained by a series of factors. First, we cannot exclude 
different adaptations that may have occurred in the 
epathic function of dams from either group, depend-
ing from a different pace of drug ingestion; second, 
and more likely, the drinking habits of dams may have 
Table 2 
Calculated repeatability (intra-day) and within-laboratory reproducibility (inter-day) for the LC-MS/MS method for analysis of nico-
tine (NC) and cotinine (CT)
Repeatability (intra-day)
I level:
0.65 ng/mL (NC, CT)
II level:
2.55 ng/mL (NC), 2.63 ng/mL (CT)
III level:
10.20 ng/mL (NC), 10.50 ng/mL (CT)
Day 1 Analyte Mean SD CV% Analyte Mean SD CV% Analyte Mean SD CV%
NC 0.60 0.06 10.52 NC 2.50 0.18 7.01 NC 9.48 0.23 2.39
CT 0.52 0.04 8.14 CT 3.18 0.19 5.92 CT 11.10 0.32 2.85
Day 2 Analyte Mean SD CV% Analyte Mean SD CV% Analyte Mean SD CV%
NC 0.53 0.06 10.66 NC 2.63 0.14 5.30 NC 10.24 0.37 3.58
CT 0.61 0.06 9.42 CT 3.29 0.21 6.37 CT 12.68 0.29 2.27
Day 3 Analyte Mean SD CV% Analyte Mean SD CV% Analyte Mean SD CV%
NC 0.55 0.06 10.38 NC 2.53 0.14 5.62 NC 9.88 0.26 2.61
CT 0.63 0.05 7.89 CT 2.87 0.17 6.01 CT 11.96 0.25 2.09
Within-laboratory reproducibility (inter-day)
I level:
0.65 ng/mL (NC, CT)
II level:
2.55 ng/mL (NC), 2.63 ng/mL (CT)
III level:
10.20 ng/mL (NC), 10.50 ng/mL (CT)
Analyte Mean SD CV% Analyte Mean SD CV% Analyte Mean SD CV%
NC 0.56 0.06 11.04 NC 2.55 0.15 5.93 NC 9.87 0.41 4.20
CT 0.59 0.07 11.53 CT 3.12 0.28 8.93 CT 12.06 0.69 5.74
SD: standard deviation; CV: coefficient of variation.
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changed differentially due to free versus unavoidable 
offer of a psychoactive but bitter fluid. As just a possi-
bility, “yoked-intake” mothers shall drink nicotine solu-
tions as the only source of fluid when they are thirsty, 
while “freely choosing” dams may titrate nicotine in-
take, and dilute its psychoactive effects and perhaps its 
taste with water. It was far beyond our present purposes 
to provide such a detailed account, which could well be 
studied in further experiments. In our hands, the focus 
of present work was just to confirm the transfer of nico-
tine to pups as well as to calibrate the method for its 
quantification.
CONCLUSIONS
We developed and validated a reliable method for 
quantification of nicotine and its metabolite cotinine in 
plasma samples by LC–MS/MS showing good results 
for linearity, precision, and recovery. Inter-day repeat-
ability percentages (inter-day CV%) were below 12.0% 
for both nicotine and cotinine at LOQ values and below 
9.0% at other concentration levels within the matrix cal-
ibration interval. Inter-day recovery ranged from 86.2% 
to 118.8% for both the analytes. 
Finally, the present method was successfully em-
ployed to investigate the passage of nicotine from Wi-
star rat dams to their offspring through breast milk, to 
quantify its major metabolite, cotinine, and to ascertain 
whether the way of nicotine assumption (free-choice 
versus forced) may influence the nicotine results. In 
particular, we quantified their concentrations in plas-
ma from pups whose mothers were orally administered 
with nicotine (two different nicotine consumption 
ways, “free-choice” versus “forced and yoked”) during 
lactation. We detected both analytes in the offspring 
plasma: nicotine was found in the 67% of plasma sam-
ples from free-choice drinking group (1.30 ± 0.31 ng/
mL) and in the 60% of plasma samples from “forced / 
yoked-intake” group (1.19 ± 0.62 ng/mL); cotinine was 
found in all samples from free-choice drinking (1.92 ± 
0.77 ng/mL) versus “forced/yoked-intake” (1.43 ± 0.30 
ng/mL) groups. As expected, comparison between the 
two nicotine exposure groups showed no significant dif-
ferences in nicotine and cotinine concentrations. 
This is the first report, to our knowledge, that nico-
tine can be directly assessed in pups’ plasma, allowing 
to verify transfer with breast feeding. Available litera-
ture only dealt with physiological parameters of rodent 
pups whose mothers were directly injected with nico-
tine during lactation [32, 33]: as such, they assumed 
implicitly that nicotine passed to pups, or based a proof 
for such assumption with detection of cotinine alone 
[34]. Therefore, observed damage may well be as-
cribed to cotinine, not nicotine transfer. Our presently 
obtained data may have implication for future studies 
about perinatal exposure to nicotine, in that they do 
give an evidence-based support for evaluating the cor-
relation between the way of exposure, the plasmatic 
concentration and the consequent effects and sequelae 
over the offspring.
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